Risultati della ricerca - Kathy Boxall

  • Mostra 1 - 11 risultati su 11
Raffina i risultati
  1. 1
    Design of Potent and Selective Hybrid Inhibitors of the Mitotic Kinase Nek2: Structure–Activity Relationship, Structural Biology, and Cellular Activity

    Design of Potent and Selective Hybrid Inhibitors of the Mitotic Kinase Nek2: Structure–Activity Relationship, Structural Biology, and Cellular Activity di Paolo Innocenti, Kwai-Ming J. Cheung, Savade Solanki, Corine Mas-Droux, Fiona Rowan, Sharon Yeoh, Kathy Boxall, Maura Westlake, Lisa Pickard, Tara Hardy, Joanne E. Baxter, G. Wynne Aherne, Richard Bayliss, Andrew M. Fry, Swen Hoelder

    Pubblicazione 2012
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  2. 2
    The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

    The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 di Michael I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis de Haven Brandon, Gary Box, Kathy Boxall, G. Wynne Aherne, Suzanne A. Eccles, Florence I. Raynaud, D. H. Williams, John Reader, Ian Collins, Michelle D. Garrett

    Pubblicazione 2010
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization

    Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization di Daniel K. Whelligan, Savade Solanki, Dawn Taylor, Douglas W. Thomson, Kwai-Ming J. Cheung, Kathy Boxall, Corine Mas-Droux, Caterina Barillari, Samantha Burns, Charles G. Grummitt, Ian Collins, Rob L. M. van Montfort, G. Wynne Aherne, Richard Bayliss, Swen Hoelder

    Pubblicazione 2010
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms

    Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms di Lisa Wright, Xavier Barril, Brian Dymock, Louisa Sheridan, A.E. Surgenor, Mandy Beswick, Martin J. Drysdale, Adam J. Collier, Andy Massey, Nicholas G. Davies, Alex Fink, Christophe Fromont, Wynne Aherne, Kathy Boxall, Swee Y. Sharp, Paul Workman, Roderick E. Hubbard

    Pubblicazione 2004
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

    CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs di Mike I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis K. de Haven Brandon, Gary Box, Albert Hallsworth, Elizabeth Smith, Kathy Boxall, Michael Lainchbury, Thomas P. Matthews, Yann Jamin, Simon P. Robinson, G. Wynne Aherne, John Reader, Louis Chesler, Florence I. Raynaud, Suzanne A. Eccles, Ian Collins, Michelle D. Garrett

    Pubblicazione 2012
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    <i>In vitro</i> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors

    <i>In vitro</i> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors di Swee Y. Sharp, Kathy Boxall, Martin Rowlands, Chrisostomos Prodromou, S. Mark Roe, Alison Maloney, Marissa Powers, Paul A. Clarke, Gary Box, Sharon Sanderson, Lisa Patterson, Thomas P. Matthews, Kwai-Ming J. Cheung, Karen Ball, Angela Hayes, Florence I. Raynaud, Richard Marais, Laurence H. Pearl, Sue Eccles, Wynne Aherne, Edward McDonald, Paul Workman

    Pubblicazione 2007
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  7. 7
    The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

    The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma di Mike I. Walton, Paul D. Eve, Angela Hayes, Alan T. Henley, Melanie Valenti, Alexis K. de Haven Brandon, Gary Box, Kathy Boxall, Matthew Tall, Karen E. Swales, Thomas P. Matthews, Tatiana McHardy, Michael Lainchbury, James Osborne, Jill V. Hunter, Neil D. Perkins, G. Wynne Aherne, John Reader, Florence I. Raynaud, Suzanne A. Eccles, Ian Collins, Michelle D. Garrett

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    Structure-Based Design of Orally Bioavailable 1<i>H</i>-Pyrrolo[3,2-<i>c</i>]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)

    Structure-Based Design of Orally Bioavailable 1<i>H</i>-Pyrrolo[3,2-<i>c</i>]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1) di Sébastien Naud, Isaac M. Westwood, Amir Faisal, Peter Sheldrake, Vassilios Bavetsias, Butrus Atrash, Kwai-Ming J. Cheung, Manjuan Liu, Angela Hayes, Jessica Schmitt, Amy Wood, Vanessa Choi, Kathy Boxall, Grace Wing-Yan Mak, Mark D. Gurden, Melanie Valenti, Alexis de Haven Brandon, Alan T. Henley, Ross A. Baker, Craig McAndrew, Berry Matijssen, Rosemary Burke, Swen Hoelder, Suzanne A. Eccles, Florence I. Raynaud, Spiros Linardopoulos, Rob L. M. van Montfort, Julian Blagg

    Pubblicazione 2013
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Inhibition of the heat shock protein 90 molecular chaperone <i>in vitro</i> and <i>in vivo</i> by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

    Inhibition of the heat shock protein 90 molecular chaperone <i>in vitro</i> and <i>in vivo</i> by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues di Swee Y. Sharp, Chrisostomos Prodromou, Kathy Boxall, Marissa Powers, Joanna L. Holmes, Gary Box, Thomas P. Matthews, Kwai-Ming J. Cheung, Andrew Kalusa, Karen James, Angela Hayes, Anthea Hardcastle, Brian Dymock, Paul A. Brough, Xavier Barril, Julie E. Cansfield, Lisa Wright, A.E. Surgenor, Nicolas Foloppe, Roderick E. Hubbard, Wynne Aherne, Laurence H. Pearl, Keith Jones, Edward McDonald, Florence I. Raynaud, Sue Eccles, Martin J. Drysdale, Paul Workman

    Pubblicazione 2007
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing

    Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing di John Reader, Thomas P. Matthews, Suki Klair, Kwai-Ming J. Cheung, Jane Scanlon, Nicolas Proisy, Glynn Addison, John Ellard, Nelly Piton, Suzanne Taylor, Michael Cherry, Martin Fisher, Kathy Boxall, Samantha Burns, Michael I. Walton, Isaac M. Westwood, Angela Hayes, Paul D. Eve, Melanie Valenti, Alexis de Haven Brandon, Gary Box, Rob L. M. van Montfort, D. H. Williams, G. Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Michelle D. Garrett, Ian Collins

    Pubblicazione 2011
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

    NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis di Suzanne A. Eccles, Andy Massey, Florence I. Raynaud, Swee Y. Sharp, Gary Box, Melanie Valenti, Lisa Patterson, Alexis de Haven Brandon, Sharon Gowan, Frances Boxall, Wynne Aherne, Martin Rowlands, Angela Hayes, Vanessa Martins, Frederique Urban, Kathy Boxall, Chrisostomos Prodromou, Laurence H. Pearl, Karen James, Thomas P. Matthews, Kwai-Ming J. Cheung, Andrew Kalusa, Keith Jones, Edward McDonald, Xavier Barril, Paul A. Brough, Julie E. Cansfield, Brian Dymock, Martin J. Drysdale, Harry Finch, Rob Howes, Roderick E. Hubbard, Alan Surgenor, Paul Webb, Mike Wood, Lisa Wright, Paul Workman

    Pubblicazione 2008
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: